Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Oruka Therapeutics, Inc.(ORKA)
Top performer 
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ORKA
09/28/2026: ORKA (5-star) is currently NOT-A-BUY. Pass it for now.
Oruka Therapeutics is a clinical-stage biotechnology company that emerged in 2024 to focus on developing next-generation biologics for chronic skin conditions. Its main strength lies in a specialized pipeline targeting the IL-23 pathway, with a focus on improving patient convenience through reduced dosing frequency. The investment story centers on the potential of ORKA-001 and ORKA-002 to compete with established biologics. However, the company faces significant risks, including the inherent uncertainty of clinical development, lack of current revenue, and intense competition from industry incumbents. This stock is best suited for risk-tolerant, long-term biotech investors who should closely monitor clinical trial updates and potential strategic partnerships.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential linked to clinical success but carries significant binary development risk. |
| Momentum investor | Mixed fit | Momentum may be driven by clinical data readouts rather than traditional financial trends. |
| Value investor | Weak fit | The company lacks stable cash flows or earnings, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and prioritizes R&D capital expenditure. |
| Low-risk investor | Weak fit | High clinical and regulatory uncertainty makes this unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks frequently experience significant price swings based on trial results and regulatory news. |
| Valuation risk | Medium / high | Valuations are highly speculative and contingent on future successful product commercialization. |
| Competition risk (Biologics incumbents) | High | Well-capitalized competitors dominate the dermatology market, creating high barriers to entry. |
| Business quality | Medium | The company is in the early stages of establishing its franchise and operational footprint. |
| Dividend income | Low / none | No dividend payments are anticipated in the foreseeable future. |
| Execution risk | High | The primary risk is the successful execution of complex clinical trials and subsequent regulatory approval. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 493.68% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.57B USD | Price to earnings Ratio - | 1Y Target Price 155 |
Price to earnings Ratio - | 1Y Target Price 155 | ||
Volume (30-day avg) 899.7K shares | Beta -0.21 | 52 Weeks Range 18.19 - 115.52 | Updated Date 09/29/2026 |
52 Weeks Range 18.19 - 115.52 | Updated Date 09/29/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.04 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Advancing IL-23p19 inhibitor assets toward potential regulatory approval. | The company currently spends money to develop medicine and expects to earn revenue only after successfully bringing products to market. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5.08B | Price to Sales(TTM) - |
Enterprise Value 5.08B | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 66.21M | Shares Floating 56.89M |
Shares Outstanding 66.21M | Shares Floating 56.89M | ||
Percent Insiders 1.26 | Percent Institutions 116.6 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Oruka Therapeutics, Inc.
Exchange NASDAQ | Headquarters Menlo Park, CA, United States | ||
IPO Launch date 1997-08-08 | President, CEO & Director Dr. Lawrence Otto Klein Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 68 | Website https://orukatx.com |
Full time employees 68 | Website https://orukatx.com | ||
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.